HENN’s Post

Take a look at this article, co-authored by Zhe Liu, PhD, Labcorp staff scientist, which focuses on development of a preclinical anti-AAV antibody assay to enable screening for pre-existing AAV immunity. Discover how this assay can help gene therapy developers identify potential low-responding individuals, increase the likelihood of successful transduction and maximize the utility of the preclinical investigations. Read the full article: http://spr.ly/6040pXp5E #GeneTherapy #AAV #CellandGeneTherapy

#Gene and #cell-based therapies have the potential to provide targeted and personalized treatments, according to Charité - Universitätsmedizin Berlin and Bayer. They are a beacon of hope for people for whom conventional therapies have failed or for whom there is no treatment so far. With Charité and Bayer, two partners for major medical progress are coming together who will establish a new center for gene and cell therapy in #Berlin, which is to be established in 2025. More information in first comment #healthforall #teambayer

#Webinar now available on demand! Expanding access to gene therapies through novel cell lines and dPCR technologies Featuring Agathos Biologics’ Jagadish Loganathan (Director, Research & Development), Andrzej Noyszewski (R&D Scientist), and Mark Voigt (Director, Business Development & Operations) where they explore how #cell line selection can drive further improvements in #AAV production, reducing costs and improving scalability. Watch this webinar to: • Explore the intersection of novel cell lines and digital polymerase chain reaction (#dPCR) technologies • Gain insight into the development, applications, and potential of the novel cell line BHK-[wt E1] • Discover how dPCR enables comprehensive evaluation of AAV production, paving the way for advancements in the field

The bioanalytical requirements and regulatory expectations for evaluating safety and efficacy of cell therapy programs have evolved considerably in recent years. As living cells, these therapeutics have the potential to expand and persist in the patient’s body, requiring more detailed evaluations of cellular dynamics after administration. Read the latest blog in our cell and gene therapy blog series where Scientific Officer Michelle Miller, PhD, DABT provides an overview of cell therapies and key points to consider when establishing your bioanalytical strategy. https://bit.ly/3OQq8gh #celltherapy #bioanalysis #Bioanalytical #pharmacokinetics #immunogenicity #drugdevelopment

Attending the 30th Annual European Society of Gene and Cell Therapy Congress in Brussels this week? Learn about how the Kytopen team has optimized transfection with #Flowfect® for natural killer cells and RNP! Stop by the poster sessions to see Gretchen Lewis Wednesday and Thursday evenings and learn more. #cellandgenetherapy #celltherapymanufacturing #esgct #nonviral

We recognize the rapid growth of broad applications for cell and gene therapies. Nevertheless, we acknowledge that there are several hurdles that must be overcome for cell therapy to enter trials. This is why our whitepaper, "Accelerate Innovation and Manufacturing to Better Serve Patients," holds immense importance. Our aim is to emphasize the critical factors in the product development cycle of cell therapy biotech drug developers, so that they can confidently overcome these hurdles. 🎓👩🎓👨🎓 Download the whitepaper today and let's revolutionize the world of cell therapy together! 🌍🔬 ➡️https://hubs.la/Q01YdWqv0 #CellTherapy #DrugDevelopment #Innovation #Manufacturing #GenscriptProBio #BetterPatientOutcomes

Dive into a thought-provoking exploration with imec's Peter Peumans, Natalie Caspari, and Maarten De Groof. They reflect on a roundtable from Advanced Therapies Week 2023, discussing the transformative potential of deep tech in cell and gene therapy development. With breakthroughs like CAR-T cell therapies, the future looks promising. Yet, the journey from a "black-box" approach to a quality-controlled, efficient drug manufacturing process is crucial. Want to delve deeper? Download the full article or explore imec’s White Paper on enhancing cell therapy product manufacturing. 🔗 https://lnkd.in/eFucCW3k #CellAndGeneTherapy #imec #AdvancedTherapiesWeek2023

🧬 Are you looking to optimize the manufacturing process of CAR-T therapies from research to commercial production (GMP)? 📍Visit our booth #18 this week in Brussels at the European Society of Gene and Cell Therapy Congress to hear more about how we can support your cell therapy development for CAR-T cells. #viralvector #celltherapy #ESGCT

Oxford Biomedica PLC said it is acquiring ABL Europe for €15 million from France's Institut Mérieux - a deal that positions it as a global pure-play contract development and manufacturing (CDMO) group in the cell and gene therapy sector. ABL Europe, a European CDMO specialising in biotech and biopharma solutions, including gene therapy and vaccine candidates, will enhance Oxford Biomedica’s international presence, especially within the European Union, with facilities in Lyon and Strasbourg. ABL Europe is engaged in more than 10 cell and gene therapy programmes across various disease areas and is expected to generate revenues of approximately €15 million for the year ending 31 December 2023. ABL Europe's forecast revenues are €15 million and last year it reported an underlying loss of €1.7 million. In early trade, the shares were up 1.55% at 170.6p. More at #Proactive #ProactiveInvestors http://ow.ly/WnjU1054Atz

Our mission is to enable widespread patient access to lifesaving cell and gene therapies. Here's how we're making this a reality... Collaborations with our LEAP partners have provided invaluable feasibility data for IRO®, demonstrating performance in real-world scenarios. At this year's ISCT, Jason Bock, Founder and CEO of CTMC shared his direct experience using the platform. Here are his key insights: 👇 ➡️ Automate Better Biology IRO® delivered higher CAR+ yields and more efficient transduction (~69% vs ~45%) versus the control. ➡️ Accelerate Product Development Process establishment on IRO® took <5 weeks from kick-off, and met all target release criteria by day 6 across two independent sites. ➡️ Scale Your Impact Vector copy number remained below the FDA-recommended <5 per transduced cell, meaning IRO® maintained safety and consistency. By empowering scientists with a new standard of tools for therapy development, we're pushing the boundaries in CGT manufacturing to enable widespread patient access and scale the impact of advanced therapies. Read more of our case study data: https://lnkd.in/gKUgg39R #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact CTMC / A joint venture between Resilience + MD Anderson Cancer Center